<DOC>
	<DOCNO>NCT01485926</DOCNO>
	<brief_summary>The primary objective : -To ass efficacy TCH TCHL neo-adjuvant treatment HER-2 positive breast cancer , use pathological complete response ( pCR ) primary endpoint ( Phase II ) . Secondary objective : - To assess clinical response rate overall response rate docetaxel carboplatin trastuzumab alone trastuzumab combined lapatinib HER-2 positive breast cancer . - To assess relationship drug exposure adverse event . - To examine potential molecular pharmacological marker response trastuzumab lapatinib - To assess Disease-free Survival ( DFS ) Overall Survival ( OS ) - To determine prophylactic Loperamide significantly reduce number diarrhoea -related adverse event .</brief_summary>
	<brief_title>A Phase II Neo-adjuvant Study Assessing TCH ( Docetaxel , Carboplatin Trastuzumab ) TCHL ( Docetaxel , Carboplatin , Trastuzumab Lapatinib ) HER-2 Positive Breast Cancer Patients .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Written inform consent obtain prior studyrelated procedure 2 . Age &gt; 18 year 3 . Histologically proven breast cancer , neoadjuvant chemotherapy trastuzumab consider valid therapeutic strategy . 4 . Patients follow TNM stage ( refer AJCC 7th Edition Appendix M ) breast cancer eligible : T2 , T3 , T4a , T4b , T4c , T4d node negative node positive ( histologically cytologically confirm ) Any T lymph node positive disease ( histologically cytologically confirm ) Patients multifocal tumour exclude ; T stage assignment must base large tumour . Patients present bilateral breast cancer eligible 5 . Tumour HER2/neu positive ( 3+ IHC fluorescence situ hybridization ( FISH ) positive ) 6 . Oestrogen progesterone receptor status know prior study entry 7 . ECOG performance status score &lt; equal 1 8 . Cardiac ejection fraction ≥ 50 % measure echocardiogram MUGA scan within 3 month prior randomisation . Note baseline treatment scan perform use modality preferably institution 9 . The effect lapatinib develop human foetus recommend therapeutic dose unknown . For reason , woman childbearing potential men must agree use adequate contraception ( nonhormonal barrier method birth control , abstinence vasectomy partner ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . If applicable , postmenopausal status define patient amenorrheic &gt; 1 year short duration FSH , LH and/or oestradiol level within postmenopausal range 10 . Patient accessible willing comply treatment , tissue acquisition follow . 11 . Formalinfixed paraffinembedded tissue available diagnostic biopsy and/or definitive surgical intervention Where possible fresh frozen tissue seek outline per protocol . 12 . Adequate bone marrow function within 14 day prior randomisation define follow laboratory value 1 . Absolute neutrophil count ≥ 1.0 x 10^9/L 2 . Haemoglobin ≥ 9.0 g/dL 3 . Platelet count ≥ 100 x 10^9/L 13 . Adequate renal function within 14 day prior randomisation define : 1 . Serum creatinine &lt; equal 1.25 x upper limit normal ( ULN ) , define institution 2 . Serum creatinine clearance &gt; 60 mg/ml/min 14 . Adequate hepatic function within 14 day prior randomisation define : 1 . Total bilirubin &lt; equal 1.0 x upper limit normal ( ULN ) . Patients Gilbert 's syndrome prior study entry must total bilirubin &lt; 3X ULN . 2 . Alkaline phosphatase AST/ALT within parameter specify protocol . 15 . Able swallow retain oral medication 16 . Patients must deem potentially operable follow neoadjuvant treatment . 1 . Prior therapy systemic cytotoxic chemotherapy Lapatinib Trastuzumab . 2 . Prior taxanes 3 . Radiotherapy ( Except radiotherapy localise radiotherapy primary squamous basal cell skin cancer ) . 4 . Patients metastatic disease ( M1 ) . 5 . Concurrent therapy nonprotocol anticancer therapy 6 . History malignancy within past 5 year , exception nonmelanoma skin cancer , situ carcinoma breast ( ductal lobular ) carcinomainsitu cervix . 7 . Current therapy hormonal agent raloxifene , tamoxifen , selective oestrogen receptor modulators ( SERMs ) , either osteoporosis prevention breast cancer . Patients must discontinue agent 14 day prior enrolment . 8 . Concurrent treatment ovarian hormonal replacement therapy . Prior treatment must stop prior enrolment . 9 . Preexisting motor sensory neurotoxicity severity ≥ Grade 2 NCICTCAE version 4.0 . 10 . Poorly control hypertension ( e.g . systolic &gt; 180mm Hg diastolic &gt; 100mm Hg . ) 11 . Any history myocardial infarction , angina pectoris congestive heart failure . Patients current therapy arrythmias exclude . For patient history selflimiting cardiac dieases ( e.g . pericarditis , temporary secondary arrythmias ) 1 year must past prior enrolment study 12 . Inflammatory bowel disease bowel condition cause chronic diarrhoea , require active therapy . 13 . Active , uncontrolled infection require parenteral antimicrobial condition require maintenance therapeutic ( i.e . nonreplacement ) dose corticosteroid . 14 . The presence medical psychiatric disorder , opinion treat physician , would contraindicate use drug protocol place patient undue risk treatment complication 15 . Male patient . 16 . Patients know hypersensitivity Chinese hamster ovary product recombinant human humanize antibody and/or know hypersensitivity study drug ingredient ( eg , polysorbate 80 docetaxel ) 17 . Pregnant woman exclude study lapatinib member 4anilinoquinazoline class kinase inhibitor potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother lapatinib , breastfeed discontinue mother treated lapatinib 18 . HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction lapatinib . Appropriate study undertake patient receive combination antiretroviral therapy indicate . 19 . Patients GI tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's , ulcerative colitis ) . 20 . Concomitant requirement medication classify CYP3A4 inducer inhibitor define Table 2 . 21 . Have current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>